

Munich, August 9th, 2023

PPF to participate in formation of leading new European biotech manufacturer

Sinfonie Life Science Management and Alira Health acted as strategic advisors to SCTbio and PPF Biotech Group in this transaction with eureKING, the first European healthcare SPAC dedicated to biomanufacturing.

- PPF Biotech has signed an agreement to contribute the assets of SCTbio (SCT Cell Manufacturing s.r.o.) to eureKING, a French special purpose acquisition company, or SPAC. Following the transaction's closing, PPF Biotech will retain minority shareholdings in eureKING. Together the transaction partners will enter into a joint initiative to build a new European contract development and manufacturing organization (CDMO) leader in biotechnology that will be listed on the Euronext stock exchange in Paris, France.
- PPF Biotech is the biotechnology division of PPF Group and eureKING is the first European healthcare SPAC dedicated to bioproduction. SCTbio is a full-service CDMO specializing in cell-based therapy and viral vectors.
- The proposed transaction values SCTbio assets at circa EUR 19.5 million. The acquisition of SCTbio by eureKING will be transacted for a cash consideration of EUR 13.08 million for 67% SCTbio shares held by PPF Biotech, and the remaining PPF Biotech-held 33% SCTbio stake will be settled by newly issued shares of eureKING. After the completion SCTbio will be fully owned by eureKING.
- The SCTbio transaction will complement eureKING's ongoing proposed acquisition of Skyepharma Production SAS, a fully integrated bio-CDMO specialized in biologics. Both transactions will allow eureKING to extend its activities in the biomanufacturing sector.
- SCTbio will continue to provide cell & gene manufacturing and related services to SOTIO Biotech from PPF Group.
- The transaction is expected to close during the last quarter of this year, subject to regulatory approval.

Notes for Editors

Sinfonie Life Science Management provides strategic and operational advice and services to the life sciences industry worldwide. Sinfonie is specialized in strategic and operational advice and assistance to different stakeholders in the life sciences industry, such as transaction advisory to the buy and sell side as well as business development and licensing.

www.sinfonie.biz

Alira Health is a global healthcare firm whose mission is to humanize healthcare and life sciences in partnership with patients. From development to medical care, we complement the expertise of our Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle, including clinical operations, real-world evidence, and patient-centric technology offerings.

Alira Health's integrated and multidisciplinary team of over 800 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50 MedTech companies and 75% of the top 50 Pharma companies.

www.alirahealth.com

SCTbio is a leading European cell-based therapy and retroviruses vector CDMO. SCTbio was founded in 2021 following its spin-off from SOTIO, a clinical stage immuno-oncology company. The company delivers high-quality collaboration in cell and gene therapy companies through a range of services which ensure GMP compliance for the full drug development life cycle, including technology transfers, process development, clinical manufacturing services, fill & finish, quality control, QA/QP release, storage and logistics. Both SOTIO and SCTbio are owned by PPF Group.

www.sctbio.com

PPF Biotech is the biotechnology division of PPF Group. The company is active in the healthcare industry and dedicated to developing and manufacturing cancer immunotherapies. SOTIO Biotech, a clinical stage immuno-oncology company, is a key PPF Biotech holding.

PPF Group operates in 26 countries, investing in multiple sectors, including biotechnology, telecommunications, media, financial services and e-commerce. PPF Group's geographic footprint spans Europe, North America and Asia. The Group owns assets to the value of EUR 40 billion and employs 61,000 people globally (as of 31 December 2022).

www.ppf.eu

eureKING, is a French SPAC (Special Purpose Acquisition Company) formed with the aim of acquiring European companies in the field of cutting-edge biomanufacturing, with the ambition of creating a leading bio-CDMO in Europe capable of meeting the growing outsourcing needs of this industry. eureKING has chosen to focus on three highly specialized and strategic segments of the biopharmaceutical industry: the production of biologics, in particular new generations of monoclonal antibodies or complex proteins, the production of cell and gene therapies and the production of live biotherapeutics (with applications in the microbiome).

eureKING is listed on the professional compartment of Euronext Paris since May 12, 2022.

www.eureking.com



Contacts - Sinfonie Life Science Management

Dr. Martin Pöhlchen
Sinfonie Life Science Management GmbH
Managing Director
T +49 89 41614220
contact@sinfonie.biz

Contacts - Alira Health

Alexandra Wollersheim
Alira Health GmbH
Partner, Transaction Advisory
T +49 89 89558070
Alexandra.wollersheim@alirahealth.com